Why ASLAN Pharmaceuticals (ASLN) Shares Are Down 40%
Why ASLAN Pharmaceuticals (ASLN) Shares Are Down 40%
ASLAN Pharmaceuticals Ltd (NASDAQ:ASLN) shares are trading lower by 38.7% to $0.68 during Wednesday's session after the company announced that its Singapore-incorporated, sole operating subsidiary has filed for voluntary liquidation.
ASLAN Pharmaceuticals Ltd (納斯達克:ASLN)股票在週三交易中下跌38.7%，報0.68美元股，此前該公司宣佈其在新加坡註冊的唯一運營子公司已申請自願清算。
The company says this decision was made following a thorough review of ASLAN SG's financial situation and strategic options. As a result, all employees of ASLAN SG and its subsidiary in the USA have been terminated.
該公司表示，經過對ASLAN SG的財務狀況和戰略選擇進行全面審查後作出了這個決定。因此，ASLAN SG及其在美國的子公司的所有員工已被解僱。
The directors of ASLAN SG resolved that the subsidiary could not continue its business due to its liabilities. Luke Anthony Furler and Tan Kim Han of Quantuma (Singapore) Pte Limited were appointed as provisional liquidators to manage the winding up of ASLAN SG's affairs.
ASLAN SG的董事會決定，由於其負債，子公司無法繼續經營。Quantuma (Singapore) Pte Limited的Luke Anthony Furler和Tan Kim Han被任命爲臨時清算人，管理ASLAN SG公務的清算。
Read Also: Fed Rate Cut Expectations Drop Mortgage Rates To 4-Month Lows: Surge In New Applications, Refinance Demand
閱讀相關內容：聯儲降息預期使抵押貸款利率降至4個月低點：新申請和再融資需求激增
They will seek strategic alternatives for ASLAN's development programs and assets, settle obligations, and distribute remaining proceeds to creditors and shareholders according to Singaporean law.
他們將爲ASLAN的發展計劃和資產尋求戰略替代方案，解決債務，並根據新加坡法律向債權人和股東分配剩餘收益。
The parent company, ASLAN Pharmaceuticals, also resolved to apply for liquidation under Cayman law due to its liabilities. Previously, the company received a delisting notice from the Nasdaq Stock Market for failing to meet listing requirements and will move its trading to the over-the-counter market.
母公司ASLAN Pharmaceuticals也決定根據開曼法律申請清算，因爲其負債。此前，該公司因未能符合上市要求而收到納斯達克股票市場的退市通知，並將其交易轉移到場外市場。
ASLN has a 52-week high of $25.44 and a 52-week low of $0.48.
ASLN的52周最高價爲25.44美元，52周最低價爲0.48美元。